Sugi Predict

Sugi Predict / Compounds / SCHEMBL346020

SCHEMBL346020

SCHEMBL346020

CC(SSc1ccccn1)c1ccccc1C(=O)NCCCCCC(=O)ON1C(=O)CC(S(=O)(=O)O)C1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ HCRTR1 O43613 1/20 0.31
▸ HDAC3 O15379 4/20 0.31
▸ HDAC1 Q13547 4/20 0.31
▸ HDAC4 P56524 2/20 0.31
▸ HDAC7 Q8WUI4 2/20 0.31
▸ HDAC2 Q92769 2/20 0.31
▸ HDAC10 Q969S8 2/20 0.31
▸ HDAC11 Q96DB2 2/20 0.31
▸ HDAC8 Q9BY41 2/20 0.31
▸ HDAC6 Q9UBN7 2/20 0.31
▸ HDAC9 Q9UKV0 2/20 0.31
▸ HDAC5 Q9UQL6 2/20 0.31
▸ PDPK1 O15530 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ HTT P42858 1/20 0.30
▸ L3MBTL1 Q9Y468 1/20 0.30
▸ DRD2 P14416 1/20 0.30
▸ DRD3 P35462 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30031578 1.00 ALDH1A1 (0.33) ALDH1A1SMN1; SMN2HCRTR1HDAC3HDAC1
SCHEMBL5051008 0.93 ALDH1A1 (0.34) ALDH1A1SMN1; SMN2HCRTR1HDAC3HDAC1
SCHEMBL321300 0.89 SMN1; SMN2 (0.35) ALDH1A1SMN1; SMN2HDAC3HDAC6KMT2A
SCHEMBL182506 0.88 — —
SCHEMBL16491630 0.84 HDAC6 (0.35) ALDH1A1SMN1; SMN2HDAC3HDAC6KMT2A
SCHEMBL900949 0.83 SMN1; SMN2 (0.36) ALDH1A1SMN1; SMN2HDAC3HDAC6KMT2A
SCHEMBL8741061 0.82 SMN1; SMN2 (0.32) ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC4
SCHEMBL9136880 0.81 ALDH1A1 (0.34) ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC4
SCHEMBL44111 0.81 HPGD (0.37) ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC4
SCHEMBL29361373 0.81 HPGD (0.37) ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240197853-A1 MULTIVALENT CHOLERA MULTIEPITOPE FUSION ANTIGEN (MEFA) AND METHODS OF USE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-06-20 — — US disclosed
WO-2022117731-A9 ELECTROSTATIC NANOPARTICLES AND USE THEREOF Westfälische Wilhelms-Universität Münster (DE) 2024-05-16 — — WO disclosed
US-20240115686-A1 SHIGELLA MULTI-EPITOPE FUSION ANTIGEN PROTEINS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2024-04-11 — — US disclosed
US-20240024500-A1 ELECTROSTATIC NANOPARTICLES AND USE THEREOF UNIVERSITÄT MÜNSTER (DE) 2024-01-25 — — US disclosed
EP-4255496-A1 ELECTROSTATIC NANOPARTICLES AND USE THEREOF Westfälische Wilhelms-Universität Münster (DE) 2023-10-11 — — EP disclosed
US-11529389-B2 Delivering biological drugs to tissues University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2022-12-20 — — US disclosed
WO-2022216734-A1 MULTIVALENT CHOLERA MULTIEPITOPE FUSION ANTIGEN (MEFA) AND METHODS OF USE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2022-10-13 — — WO disclosed
WO-2022117731-A1 ELECTROSTATIC NANOPARTICLES AND USE THEREOF Westfälische Wilhelms-Universität Münster (DE) 2022-06-09 — — WO disclosed
WO-2021076610-A1 SHIGELLA MULTI-EPITOPE FUSION ANTIGEN PROTEINS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2021-04-22 — — WO disclosed
EP-3762429-A1 DELIVERING BIOLOGICAL DRUGS TO TISSUES University of Pittsburgh - Of the Commonwealth System of Higher Education (US) 2021-01-13 — — EP disclosed
WO-1999049019-A2 LUCIFERASES, FLUORESCENT PROTEINS, NUCLEIC ACIDS ENCODING THE LUCIFERASES AND FLUORESCENT PROTEINS AND THE USE THEREOF IN DIAGNOSTICS PROLUME, LTD. (US) 1999-09-30 — — WO disclosed
EP-0923387-A2 HEPARINIZED MEDICAL DEVICES CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES Selective Genetics, Inc. (US) 1999-06-23 — — EP disclosed
WO-1998026277-A9 APPARATUS AND METHOD FOR DETECTING AND IDENTIFYING INFECTIOUS AGENTS — 1998-11-19 — — WO disclosed
WO-1998026277-A2 APPARATUS AND METHOD FOR DETECTING AND IDENTIFYING INFECTIOUS AGENTS PROLUME, LTD. (US) 1998-06-18 — — WO disclosed
WO-1997049434-A9 HEPARINIZED MEDICAL DEVICES CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES — 1998-05-07 — — WO disclosed
WO-1997049434-A2 HEPARINIZED MEDICAL DEVICES CONTAINING HEPARIN-BINDING GROWTH FACTOR CONJUGATES PRIZM PHARMACEUTICALS, INC. (US) 1997-12-31 — — WO disclosed
EP-0776218-A2 HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS PRIZM PHARMACEUTICALS, INC. (US) 1997-06-04 — — EP disclosed
WO-1996008274-A2 CONJUGATES OF HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR WITH TARGETED AGENTS PRIZM PHARMACEUTICALS, INC. (US) 1996-03-21 — — WO disclosed
WO-1996006641-A1 CONJUGATES OF VASCULAR ENDOTHELIAL GROWTH FACTOR WITH TARGETED AGENTS PRIZM PHARMACEUTICALS, INC. (US) 1996-03-07 — — WO disclosed
WO-1995024928-A2 HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS PRIZM PHARMACEUTICALS, INC. (US) 1995-09-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240024500-A1 ELECTROSTATIC NANOPARTICLES AND USE THEREOF FCGRT, NCL, EEA1 ALDH1A1 3999/4885SMN1; SMN2 2428/4885HCRTR1 4025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.